Teva general counsel proposes $1.10M share sale

The notice lists an indicative market price of $41.72 per share and names Citigroup Global Markets, Inc. as broker.

Available on EDGAR 11/04/2026 - 04:01 PM EST Accepted by SEC EDGAR 11/04/2026 - 04:00 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd. (TEVA) is the issuer named in a Rule 144 notice in which Senior VP, General Counsel and Corporate Secretary Dov Bergwerk reports a proposed sale of 26,260 ordinary shares through a stock option exercise and sale transaction dated November 4, 2026. The notice lists an indicative market price of $41.72 per share, an aggregate market value of $1,095,567.20, and Citigroup Global Markets, Inc. as broker.

Key Figures

Ordinary shares proposed for sale: 26,260 shares Indicative market price: $41.72 per share Aggregate market value: $1,095,567.20

3 metrics

Ordinary shares proposed for sale 26,260 shares Stock option exercise and sale transaction dated November 4, 2026

Indicative market price $41.72 per share Price stated in the notice remarks

Aggregate market value $1,095,567.20 For the securities listed for sale

Key Terms

Rule 144, STOCK OPTION EXERCISE AND SALE, indicative market price

3 terms

Rule 144 regulatory

"sales required by paragraph (e) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

STOCK OPTION EXERCISE AND SALE financial

"SHARES SOLD PURSUANT TO STOCK OPTION EXERCISE AND SALE TRANSACTION"

indicative market price financial

"INDICATIVE MARKET PRICE WAS 41.72"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TEVA shares did Dov Bergwerk report for sale?

Dov Bergwerk's notice covers a proposed sale of 26,260 ordinary shares through a stock option exercise and sale transaction dated November 4, 2026.

What price and value does the TEVA notice list?

The notice lists an indicative market price of $41.72 per share and an aggregate market value of $1,095,567.20 for the 26,260 ordinary shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001997381
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Bergwerk Dov
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Senior VP General Counsel Corporate Secretary

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	Citigroup Global Markets, Inc 390 Greenwich St New York NY 10013	26260	1095567.20	1166826784	11/04/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	11/04/2026	STOCK OPTION EXERCISE AND SALE	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			26260	11/04/2026	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	SHARES SOLD PURSUANT TO STOCK OPTION EXERCISE AND SALE TRANSACTION. UNDER SECTION 3D INDICATIVE MARKET PRICE WAS 41.72
Date of Notice	11/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)